Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- KEYNOTE-040 investigators
- University of California at San Diego
- Centre Hospitalier de L'Universite de Montreal
- Institut Curie
- INSERM U900
- Université Paris-Saclay
- Instituto Português de Oncologia do Porto Francisco Gentil E.P.E.
- IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
- University of Milan
- Hospital Ramon y Cajal
- Université catholique de Louvain
- University of Geneva
- Johns Hopkins University
- Yale University
- Merck
- Institute of Cancer Research
- Royal Marsden NHS Foundation Trust
Research output: Contribution to journal › Article › peer-review
1503
Link opens in a new tab
Scopus
citations